Acacia Pharma is a commercial stage biopharmaceutical company focused on developing and commercializing novel products
We aim to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy.
The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address. Acacia Pharma's portfolio comprises:
(intravenous amisulpride): approved in the US (February 2020) for the treatment and prophylaxis of postoperative nausea & vomiting (PONV) either alone or incombination with antiemetics of a different class.
(remimazolam) for injection: a very rapid onset/offset benzodiazepine sedative approved in the US (July 2020) for use during invasive medical procedures lasting 30 minutes or less, such as colonoscopy and bronchoscopy.
(intravenous and oral amisulpride): a selective dopamine antagonist in Phase 2 for chemotherapy induced nausea & vomiting (CINV).
Acacia Pharma has its own commercial infrastructure in the US through which it will sell its products directly.
Acacia Pharma intends to establish licensing and/or distribution agreements with selected pharmaceutical partners outside the US for Barhemsys® and APD403.
The Company’s management team and Board have extensive experience in the development and commercialization of hospital pharmaceutical products.
Acacia Pharma was founded in 2007 and has offices in Cambridge, UK and Indianapolis, IN, USA.